Mastodon

Streptococcal bacteriophag (Solution) Instructions for Use

Marketing Authorization Holder

Microgen NPO, JSC (Russia)

ATC Code

V03A (Other therapeutic agents)

Dosage Form

Bottle OTC Icon Streptococcal bacteriophage Oral, topical and external solution

Dosage Form, Packaging, and Composition

Solution for oral, topical and external use yellow in color, transparent.

Streptococcal bacteriophage*

*sterile phagolysate of Streptococcus strains

Excipients : 8-Hydroxyquinoline sulfate monohydrate – 0.0001 g/ml.

20 ml – bottles (4) – carton packs.
20 ml – bottles (10) – carton packs.
100 ml – bottles (1) – carton packs.

Clinical-Pharmacological Group

Immunobiological drug – bacteriophage

Pharmacological Action

The drug has the ability to specifically lyse Streptococcus bacteria.

Indications

Treatment and prevention of diseases caused by Streptococcus bacteria as part of complex therapy

  • Diseases of the ear, throat, nose, respiratory tract and lungs (inflammation of the sinuses, middle ear, tonsillitis, pharyngitis, laryngitis, tracheitis, bronchitis, pneumonia, pleurisy);
  • Surgical infections (wound suppuration, burns, abscess, phlegmon, boils, carbuncles, hidradenitis, panaritium, paraproctitis, mastitis, bursitis, osteomyelitis);
  • Urogenital infections (urethritis, cystitis, pyelonephritis, colpitis, endometritis, salpingo-oophoritis);
  • Enteral infections (gastroenterocolitis, cholecystitis), intestinal dysbiosis;
  • Generalized septic diseases;
  • Purulent-inflammatory diseases of newborns (omphalitis, pyoderma, conjunctivitis, gastroenterocolitis, sepsis, etc.);
  • Other diseases caused by streptococci.

For prophylactic purposes, the drug is used for the treatment of postoperative and freshly infected wounds, as well as for the prevention of nosocomial infections for epidemic indications.

An important condition for effective phage therapy is the preliminary determination of the phage sensitivity of the pathogen.

ICD codes

ICD-10 code Indication
A04 Other bacterial intestinal infections
A09 Other and unspecified gastroenteritis and colitis of infectious origin
A40 Streptococcal sepsis
B95 Streptococcus and Staphylococcus as the cause of diseases classified to other headings
H66 Suppurative and unspecified otitis media
J01 Acute sinusitis
J02 Acute pharyngitis
J03 Acute tonsillitis
J04 Acute laryngitis and tracheitis
J13 Pneumonia due to Streptococcus pneumoniae
J15 Bacterial pneumonia, not elsewhere classified
J20 Acute bronchitis
J31.0 Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis)
J31.2 Chronic pharyngitis
J32 Chronic sinusitis
J35.0 Chronic tonsillitis
J37 Chronic laryngitis and laryngotracheitis
J42 Unspecified chronic bronchitis
J85 Abscess of lung and mediastinum
J86 Pyothorax (pleural empyema)
K52.9 Noninfective gastroenteritis and colitis, unspecified
K61 Abscess of anal and rectal regions
K63.8 Other specified diseases of intestine
K81.0 Acute cholecystitis
K81.1 Chronic cholecystitis
L02 Cutaneous abscess, furuncle and carbuncle
L03 Cellulitis
L73.2 Hidradenitis suppurativa
M70 Soft tissue disorders related to use, overuse, and pressure
M71 Other bursopathies
M86 Osteomyelitis
N10 Acute tubulointerstitial nephritis (acute pyelonephritis)
N11 Chronic tubulointerstitial nephritis (chronic pyelonephritis)
N30 Cystitis
N34 Urethritis and urethral syndrome
N61 Inflammatory diseases of the breast
N70 Salpingitis and oophoritis
N71 Inflammatory disease of uterus, excluding cervix (including endometritis, myometritis, metritis, pyometra, uterine abscess)
N72 Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N73.5 Unspecified female pelvic peritonitis
N76 Other inflammatory diseases of vagina and vulva
O91 Infections of the breast associated with childbirth
P36 Bacterial sepsis of newborn
P38 Omphalitis of newborn with or without mild hemorrhage
P39.1 Neonatal conjunctivitis and dacryocystitis
P39.4 Neonatal skin infection
P39.8 Other specified infections specific to the perinatal period
T30 Burns and corrosions of unspecified body region
T79.3 Posttraumatic wound infection, not elsewhere classified
ICD-11 code Indication
1A01 Intestinal infection caused by other Vibrio species
1A03.Z Intestinal infections caused by Escherichia coli, unspecified
1A0Z Bacterial intestinal infections, unspecified
1A40.Z Infectious gastroenteritis or colitis, unspecified
1B70.1 Streptococcal cellulitis of the skin
1B70.2 Staphylococcal cellulitis of the skin
1B70.Z Bacterial cellulitis or lymphangitis caused by unspecified bacterium
1B75.0 Furuncle
1B75.1 Carbuncle
1B75.2 Furunculosis
1B75.3 Pyogenic skin abscess
1G40 Sepsis without septic shock
AA9Z Unspecified suppurative otitis media
CA01 Acute rhinosinusitis
CA02.Z Acute pharyngitis, unspecified
CA03.Z Acute tonsillitis, unspecified
CA05 Acute laryngitis or tracheitis
CA09.0 Chronic rhinitis
CA09.2 Chronic pharyngitis
CA0A.Z Chronic rhinosinusitis, unspecified
CA0F.Y Other specified chronic diseases of the palatine tonsils and adenoids
CA0G Chronic laryngitis or laryngotracheitis
CA20.1Z Chronic bronchitis, unspecified
CA40.07 Pneumonia due to Streptococcus pneumoniae
CA40.0Z Bacterial pneumonia, unspecified
CA42.Z Acute bronchitis, unspecified
CA43.Z Abscess of lung or mediastinum, unspecified
CA44 Pyothorax
DA90.0 Syndromic diarrhea
DA92.1 Pneumatosis intestinalis of the small intestine
DA98.Z Polyps of small intestine, unspecified
DB31.1 Pneumatosis of the colon
DB36.Z Certain infections of the colon, unspecified
DB70.0Z Abscess of anal and rectal region, unspecified
DC12.0Z Acute cholecystitis, unspecified
DC12.1 Chronic cholecystitis
DE2Z Diseases of the digestive system, unspecified
ED92.0 Hidradenitis suppurativa
EH1Z Neonatal infection of the skin, unspecified
FB50.1 Bursitis associated with use, overuse or pressure
FB50.Z Bursitis, unspecified
FB84.Z Osteomyelitis or osteitis, unspecified
GA00 Vulvitis
GA01.Z Inflammatory diseases of uterus, except cervix, unspecified
GA02.Z Unspecified vaginitis
GA05.2 Unspecified pelvic peritonitis in women
GA07.Z Salpingitis and oophoritis, unspecified
GA0Z Inflammatory diseases of female genital tract, unspecified
GB21.Z Inflammatory diseases of the breast, unspecified
GB50 Acute tubulo-interstitial nephritis
GB51 Acute pyelonephritis
GB55.Z Chronic tubulo-interstitial nephritis, unspecified
GB5Z Renal tubulo-interstitial diseases, unspecified
GC00.Z Cystitis, unspecified
GC02.Z Urethritis and urethral syndrome, unspecified
JB45.Z Infections of the breast associated with childbirth, unspecified
KA60 Fetal or neonatal sepsis
KA65.0 Conjunctivitis or dacryocystitis of newborn
KA65.1 Omphalitis of newborn
KA6Z Infections of fetus or newborn, unspecified
NE11 Burn of unspecified body region
NF0A.3 Posttraumatic wound infection, not elsewhere classified
XN2QM Gram-positive bacteria
XN3NM Streptococcus
XN9ZG Staphylococcus
GA0Z Inflammatory diseases of female genital tract, unspecified
XA5WW1 Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

The drug is used for oral administration, rectal administration, applications, irrigation, introduction into wound cavities, vagina, uterus, nose, sinuses and drained cavities.

Recommended dosages of the drug

Patient age Dose per administration (ml)
orally in enema
0-6 months 5 5-10
6-12 months 10 10-20
1 to 3 years 15 20-30
3 to 8 years 15-20 30-40
8 years and older 20-30 40-50

Treatment of purulent-inflammatory diseases with localized lesions should be carried out simultaneously both locally and by taking the drug orally for 7-20 days (according to clinical indications).

In case chemical antiseptics were used to treat the wound before applying the bacteriophage, the wound must be thoroughly rinsed with a sterile 0.9% sodium chloride solution.

Depending on the focus of infection, the bacteriophage is used:

1. In the form of irrigation, lotions and tamponage in a volume of up to 200 ml depending on the size of the affected area. In case of an abscess, after removal of the purulent contents by puncture, the drug is injected in an amount less than the volume of the removed pus. In case of osteomyelitis, after appropriate surgical treatment, 10-20 ml of bacteriophage is poured into the wound.

2. When introduced into cavities (pleural, articular and other limited cavities) up to 100 ml, a capillary drainage is left, through which the bacteriophage is injected for several days.

3. For cystitis, pyelonephritis, urethritis, the drug is taken orally. If the cavity of the bladder or renal pelvis is drained, the bacteriophage is administered through a cystostomy or nephrostomy 1-2 times a day, 20-50 ml into the bladder and 5-7 ml into the renal pelvis;

4. For purulent-inflammatory gynecological diseases, the drug is injected into the cavity of the vagina, uterus at a dose of 5-10 ml once daily,

5. For colpitis – 10 ml by irrigation or tamponage 2 times a day. Tampons are placed for 2 hours.

5. For purulent-inflammatory diseases of the ear, throat, nose, the drug is administered at a dose of 2-10 ml 1-3 times a day. The bacteriophage is used for rinsing, washing, instillation, and introduction of moistened turundas (leaving them for 1 hour).

6. For enteral infections, intestinal dysbiosis, the drug is taken orally 3 times a day 1 hour before meals for 7-20 days according to clinical indications. A combination of double oral administration with a single rectal administration of a single age dose of bacteriophage in the form of an enema after bowel movement is possible.

Use of bacteriophage in children (up to 6 months). For sepsis, enterocolitis of newborns, including premature infants, the bacteriophage is used in the form of high enemas (through a gas outlet tube or catheter) 2-3 times a day at a dose of 5-10 ml. In the absence of vomiting and regurgitation, the drug may be used orally. In this case, it is mixed with breast milk. A combination of rectal (in the form of high enemas) and oral (by mouth) administration of the drug is possible. The course of treatment is 5-15 days. In case of a recurrent course of the disease, repeated courses of treatment are possible. For the prevention of sepsis and enterocolitis in case of intrauterine infection or the risk of nosocomial infection in newborn children, the bacteriophage is used in the form of enemas 2 times a day for 5-7 days.

In the treatment of omphalitis, pyoderma, infected wounds, the drug is used in the form of applications twice daily (a gauze napkin is moistened with bacteriophage and applied to the umbilical wound or the affected area of the skin).,

Precautions for use. Before use, the bottle with bacteriophage must be shaken and inspected. The preparation must be transparent and not contain sediment.

Attention! Do not use the drug if it is cloudy!

Due to the content of a nutrient medium in the preparation, in which bacteria from the environment can develop, causing cloudiness of the preparation, it is necessary to observe the following rules when opening the bottle

  • Wash hands thoroughly;
  • Treat the cap with an alcohol-containing solution;
  • Remove the cap without opening the stopper;
  • Do not place the stopper with the inner surface on the table or other objects;
  • Do not leave the bottle open;
  • Store the opened bottle only in the refrigerator.

Opening the bottle and extracting the required volume of the drug can be carried out with a sterile syringe by puncturing the stopper.

The drug from an opened bottle, subject to storage conditions, the above rules and the absence of cloudiness, can be used throughout the entire shelf life.

Adverse Reactions

Not established.

Contraindications

  • Hypersensitivity to the components of the drug.

Use in Pregnancy and Lactation

The use of this medicinal product during pregnancy and breastfeeding is possible in the presence of infections caused by phage-sensitive strains of streptococci (as recommended by a doctor).

Pediatric Use

Used according to indications in accordance with the dosage regimen.

Special Precautions

Effect on ability to drive vehicles and mechanisms

No data available.

Overdose

Not established.

Drug Interactions

The use of bacteriophage does not exclude the use of other antibacterial drugs.

Storage Conditions

The drug is stored in accordance with SP 3.3.2.1248-03 in a dry place, protected from light and out of reach of children, at a temperature of 2 to 8°C (46.4°F).

Shelf Life

Shelf life – 2 years.

Dispensing Status

Without a prescription.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS